The Patent Finder

Fuso Pharmaceutical Industries, Ltd.

27 patents currently held · Updated Nov 17, 2026
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 6 name spellings.

4
Ending by 2030
Jul 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 11, 2027
    The maintenance fee for ANTI-PD-L1 Antibody for Detecting PD-L1 (US 11,697,686) comes due Jan 11, 2027. Unpaid by Jul 12, 2027, it lapses early.
  • 2 fees due Feb 4 to 15, 2027 · next Feb 4
  • 1 fee due Apr 10, 2027
    The maintenance fee for Vector Including a Translation-Impaired Dihydrofolate Reductase Gene Cassette and Ubiquitously Acting Chromatin Opening Element (US 11,781,146) comes due Apr 10, 2027. Unpaid by Oct 12, 2027, it lapses early.
  • 1 fee due Aug 4, 2027
    The maintenance fee for Indole Alkaloid Compound Having Immune Checkpoint Inhibitory Action (US 10,550,120) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.
  • 1 fee due Oct 28, 2027
    The maintenance fee for T-type calcium channel inhibitor (US 10,633,358) comes due Oct 28, 2027. Unpaid by Apr 28, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 9,540,658Adenovirus vector
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,096,878Expression Vector for Producing Protein Derived from Foreign Gene in Large Quantity Using Animal Cells, and Use Thereof
In force
 · High confidence
In forceHigh confidence
US 8,383,595Peptide derivative and composition for promoting tear secretion comprising the same
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,586,327Detection of bacteria belonging to the genus Campylobacter by targeting cytolethal distending toxin
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,029,627Model animal for pregnancy-induced hypertension syndrome, and treatment method therefor
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,932,867High purity heparin and production method therefor
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,540,454High purity heparin and production method therefor
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,410,120Composition for embryo culture
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,160,286Method for producing disinfected liver
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,633,358T-type calcium channel inhibitor
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 27 patents shown.
Pro members see all 27.
Pro members: see all 27 patents
Also on record, not counted in the 27: 6 patents in force now held by others · 52 lapsed for an unpaid fee · 26 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

4 pending · 12 abandoned · 18 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited